For the first time, researchers have seen how light behaves during a mysterious phenomenon called ‘imaginary time’
When you shine light through almost any transparent material, the gridlock of electromagnetic fields that make up the atomic alleys and side streets will add a significant amount of time to each photon’s commute.
This delay can tell physicists a lot about how light scatters, revealing details about the matrix of material the photons must navigate. Yet until now, one trick up the theorist’s sleeve for measuring light’s journey – invoking imaginary time – has not been fully understood in practical terms.
BYD, an electric vehicle company, is accused of cooking the books and faking profitability, potentially hiding financial issues such as a liquidity crisis and unprofitable electric vehicle business.
Questions to inspire discussion.
Financial Concerns 🚩 Q: What are the warning signs of BYD’s potential financial trouble? A: BYD is offering massive discounts of 10–30% on already affordable vehicles, with some models selling for as low as $10,000, and allegedly has a 12-month payment delay to suppliers. 💰 Q: How is BYD’s automotive business reportedly staying afloat? A: BYD’s automotive business is allegedly being carried by their highly profitable battery cell supply business, which is not separately reported in their financials, making it difficult to determine the true profitability of their electric vehicle sales.
In the fight against cancer, immunotherapy—which aims to boost the body’s natural defenses against cancer—is experiencing remarkable growth. Most of these treatments are based on CD8 T lymphocytes, “killer cells” able to eliminate diseased cells. A team from the University of Geneva (UNIGE) has explored an alternative approach involving CD4 T lymphocytes.
Long considered mere auxiliary cells, their therapeutic potential has been considered of secondary importance. But the scientists have discovered that they also have a strong killing capacity, while continuing to support other immune cells. Using cell engineering technologies, the team reprogrammed the cells to target a tumor marker found in many cancers, both in adults and children. These results, published in the journal Science Advances, offer hope for a faster therapeutic strategy that could benefit a greater number of patients.
Traditionally considered as auxiliary cells, CD4 T cells produce molecules to support the action of other immune cells by facilitating their functions, migration or proliferation in the organism. The recent work by Camilla Jandus, Assistant Professor in the Department of Pathology and Immunology, in the Center for Inflammation Research and in the Translational Research Center in Onco-hematology at the UNIGE Faculty of Medicine, shows that they have been vastly underestimated.
A new international study finds that people place greater emotional value on empathy they believe comes from humans—even when the exact same response is generated by artificial intelligence.
Published in Nature Human Behaviour, the study involved over 6,000 participants across nine experiments.
The researchers, led by Prof. Anat Perry from the Hebrew University of Jerusalem and her Ph.D. student Matan Rubin, in collaboration with Prof. Amit Goldenberg, with researchers from Harvard University and Prof. Desmond C. Ong, from the University of Texas, tested whether people perceived empathy differently depending on whether it was labeled as coming from a human or from an AI chatbot.
A collaborative project by Mass General Cancer Center researchers to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
